Evidence map›Paper›PMID 39140859›Full record

ArticleClinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis

Prognosis in Patients with ST-Segment Elevation Myocardial Infarction Reperfused by PHDP: 1-Year MACEs Follow-Up.

Jie Dou, Jie Gao, Hui-Hui Yang, Ruoling Guo, Chao Jiang, Jiang Zhou, Xiaomei Yu, Jingtao Guo, Jinlong Zhang, Donglei Luo

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jie DouSchool of Medicine, Chengde Medical University, Chengde 067000, Hebei, China.ORCID 0009-0002-2786-520X
Jie GaoSchool of Medicine, Chengde Medical University, Chengde 067000, Hebei, China.ORCID 0000-0002-5618-6428
Hui-Hui YangSchool of Medicine, Chengde Medical University, Chengde 067000, Hebei, China.
Ruoling GuoSchool of Medicine, Chengde Medical University, Chengde 067000, Hebei, China.
Chao JiangSchool of Medicine, Chengde Medical University, Chengde 067000, Hebei, China.
Jiang ZhouDepartment of Cardiology, Chengde Central Hospital/Second Clinical College of Chengde Medical University, Chengde 067000, Hebei, China.
Xiaomei YuDepartment of Cardiology, Chengde Central Hospital/Second Clinical College of Chengde Medical University, Chengde 067000, Hebei, China.
Jingtao GuoDepartment of Cardiology, Chengde Central Hospital/Second Clinical College of Chengde Medical University, Chengde 067000, Hebei, China.
Jinlong ZhangDepartment of Cardiology, Chengde Central Hospital/Second Clinical College of Chengde Medical University, Chengde 067000, Hebei, China.
Donglei LuoDepartment of Cardiology, Chengde Central Hospital/Second Clinical College of Chengde Medical University, Chengde 067000, Hebei, China.ORCID 0000-0003-0524-4701

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study explored 1-year follow-up of Parmaco-invasive strategy with half-dose recombinant human prourokinase (PHDP) in patients with acute ST-segment elevation myocardial infarction (STEMI). The follow-up endpoints were major adverse cardiovascular events (MACEs) occurring within 30 days and 1 year, as well as postoperative bleeding events. The study ultimately included 150 subjects, with 75 in the primary percutaneous coronary intervention (PPCI) group and 75 in the PHDP group. This study found that the PHDP group had a shorter FMC-reperfusion time (42.00 min vs 96.00 min, P < 0.001). During PCI, the PHDP group had a lower percutaneous transluminal coronary angioplasty (PTCA) (

Indexed as

ST Elevation Myocardial InfarctionAgedFemaleFollow-Up StudiesHumansMaleMiddle AgedPercutaneous Coronary InterventionPrognosisRecombinant ProteinsRecombinant Proteinsfibrinolysismajor adverse cardiovascular events‌percutaneous coronary interventionrecombinant human prourokinaseST-segment elevation myocardial infarction

Identifiers

PMID39140859
PMCPMC11325463

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.